

JINNAH MEDICAL COMPLEX AND RESEARCH CENTER

**AUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2025**

ILYAS SAEED & CO.
CHARTERED ACCOUNTANTS
A member of
mgeworldwide 

OFFICE # 26, 2ND FLOOR, ROSE PLAZA, I - 8 MARKAZ, ISLAMABAD
PH: (+92) 051 - 4938026 & 051 - 4938027, FAX: (+92) 051 - 4938028

JINNAH MEDICAL COMPLEX AND RESEARCH CENTER

STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2025


ASSETS	<u>NOTE</u>	<u>2025</u> <u>RUPEES</u>
CURRENT ASSETS		
Accrued Interest	6	3,133,370
Cash & Bank Balances	7	3,820,850,000
		3,823,983,370
TOTAL ASSETS		<u>3,823,983,370</u>
EQUITY AND LIABILITIES		
SHARE CAPITAL & FUNDS		
Authorized Share Capital	8	100,000
Issued, Subscribed & Paid-up Capital	8	100,000
General Fund	SCF	2,876,696
		2,976,696
NON-CURRENT LIABILITIES		
Restricted Funds	9	3,820,150,000
		3,820,150,000
CURRENT LIABILITIES		
Accrued & Other Liabilities	10	287,500
Provision For Taxation	11	569,174
		856,674
TOTAL EQUITY & LIABILITIES		<u>3,823,983,370</u>
Contingencies & Commitments	12	-

The annexed notes from (1) to (25) form an integral part of these financial statements.

CHIEF EXECUTIVE



DIRECTOR



JINNAH MEDICAL COMPLEX AND RESEARCH CENTER
STATEMENT OF INCOME & EXPENDITURE
AND OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED JUNE 30, 2025

PARTICULARS	<u>NOTE</u>	2025 <u>RUPEES</u>
INCOME		
Other Income	13	3,133,370 3,133,370
EXPENDITURE		
Expenses	14	287,500 287,500
Surplus For The Period Before Levies & Taxation		2,845,870
Levies	15	-
Surplus For The Period Before Taxation		2,845,870
Taxation	16	(569,174)
Net Surplus For The Period		2,276,696
Comprehensive Income / (Loss) For The Period		-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		2,276,696


Jsw

The annexed notes from (1) to (25) form an integral part of these financial statements.

CHIEF EXECUTIVE



DIRECTOR



JINNAH MEDICAL COMPLEX AND RESEARCH CENTER
STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED JUNE 30, 2025


PARTICULARS	NOTE	2025 RUPEES
CASH FLOW FROM OPERATING ACTIVITIES		
Surplus For The Period Before Levies & Taxation	I&E	2,845,870
Adjustments For Non-Cash Items:		
None	-	-
Operating Cash Flow Before Working Capital Changes	(a)	2,845,870
Working Capital Changes:		
(Increase) In Accrued Interest	6	(3,133,370)
Increase In Accrued & Other Liabilities	10	287,500
Net Working Capital Changes	(b)	(2,845,870)
Cash Generated From Operations	(a+b)	-
Less: Income Tax Paid	11	-
Net Cash Flow From Operating Activities	(A)	-
CASH FLOW FROM INVESTING ACTIVITIES		
None	-	-
Net Cash Flow From Investing Activities	(B)	-
CASH FLOW FROM FINANCING ACTIVITIES		
Issue Of Shares	8	100,000
Contribution Received	9	600,000
Restricted Fund Received	9	3,820,150,000
Net Cash Flow From Financing Activities	(C)	3,820,850,000
Net Changes In Cash & Cash Equivalents	(A+B+C)	3,820,850,000
Cash & Cash Equivalents At Start Of The Period	-	-
CASH & CASH EQUIVALENT AT END OF THE PERIOD	7	<u>3,820,850,000</u>

The annexed notes from (1) to (25) form an integral part of these financial statements.

CHIEF EXECUTIVE



DIRECTOR



JINNAH MEDICAL COMPLEX AND RESEARCH CENTER
STATEMENT OF CHANGES IN FUNDS
FOR THE PERIOD ENDED JUNE 30, 2025

PARTICULARS	SHARE CAPITAL <u>RUPEES</u>	GENERAL FUND <u>RUPEES</u>	TOTAL <u>RUPEES</u>
Opening Balance	-	-	-
Shares Issued During The Period	100,000	-	100,000
Contributions During The Period	-	600,000	600,000
Surplus For The Period	-	2,276,696	2,276,696
BALANCE AS AT JUNE 30, 2025	<u><u>100,000</u></u>	<u><u>2,876,696</u></u>	<u><u>2,976,696</u></u> <i>gsw</i>

The annexed notes from (1) to (25) form an integral part of these financial statements.

CHIEF EXECUTIVE _____

Rai

DIRECTOR _____

Harbuz